JUN 30, 2020 10:00 AM PDT

COVID-19 Serology Assays and Cell Therapy Strategies

Speakers
  • Laboratory of Dr. Florian Krammer - Department of Microbiology, Icahn School of Medicine at Mount Sinai
    Biography
      Fatima is currently a PhD candidate in the lab of Dr. Florian Krammer. Before starting her PhD, she had a deep interest in emerging RNA viruses that have no vaccines against them, such as hantaviruses as well as arenaviruses. She also worked extensively on various projects that revolved around development of a universal influenza virus vaccine that provides long-term immunity. Currently, she studies antibody responses against arenaviruses, and since the pandemic caused by SARS-CoV-2, she is studying antibody responses in humans that have had COVID-19.
    • Physician in the Division of Hematology and Oncology at Nationwide Children's Hospital and director of the Cellular Therapy and Cancer Immunology Program at Nationwide Children's Hospital
      Biography
        Dr. Lee is Professor of Pediatrics and DiMarco Family Endowed Chair in Cell Based Therapy at Nationwide Children's Hospital. He is the founding Director of the Cellular Therapy and Cancer Immunotherapy Program, a joint program between NCH and The Ohio State University James Cancer Hospital. Dr. Lee conducts clinical and translational research on natural killer (NK) cells and their potential for cancer immunotherapy. His laboratory identified a crucial role for IL-21 and STAT3 signaling in NK cell function and proliferation, which has enabled a method for large-scale propagation of clinical-grade NK cells for adoptive transfer. NK cells expanded with this approach have been infused into adult and pediatric patients with leukemia, brain tumors, and solid tumors in investigator-initiated Phase I trials. Dr. Lee is chair of the Cellular Therapy Strategy Group for the Pediatric Blood and Marrow Transplant Consortium, member of the NIH Novel and Exceptional Technology and Research Advisory Committee and member of the Cell Therapy Steering Committee of the Children's Oncology Group. His work in cancer immunotherapy and cellular therapy has been supported by NIH, DOD and numerous foundation research grants, and has led to over 100 peer-reviewed publications, patents, and commercial licenses. Dr. Lee practices clinically in the area of bone marrow transplantation, with a particular interest in haplotransplantation and cellular therapy.
      • Vice President Development & Operations, Pluristem Therapeutics Inc.
        Biography
          Lior Raviv joined Pluristem in 2011 and currently serves as vice president of Development & Operations in charge on process and technology development, Manufacturing and Operations. Prior to that, Lior served as process development engineer, projects manager and product development team leader at Pluristem in charge of new technologies and process development. Prior to joining Pluristem, Lior spent 2010-11 in the position of R&D analytical researcher at Teva Pharmaceutical Industries. He holds a master's in pharmacology from Ben-Gurion University and a bachelor's in biotechnology engineering from Ben-Gurion University.

        Abstract

        DATE:  June 30, 2020

        TIME:   10:00 am PDT, 1:00 pm EDT

         

        COVID-19 is a highly pathogenic disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We have assembled a panel of experts to discuss a variety of current strategies for both serological testing and cell therapies to combat tissue damage caused by COVID-19. 
         
        Part 1. Serological assays 
         
        Serological assays are blood-based tests that have proven to be critical in understanding whether people have been exposed to a pathogen by looking at their immune response.  This has been particularly helpful in quantifying the number of COVID-19 cases, including those that may be asymptomatic or have recovered.  Here we describe a serological assay established by the lab of Dr. Florian Krammer of Icahn School of Medicine at Mount Sinai to detect seroconversion to SARS-CoV-2 in humans. Using this assay, we can assess if people have antibodies against the spike protein of SARS-CoV-2.  
        • The assay has demonstrated high specificity and high sensitivity and has received emergency use authorization (EUA) from the Food and Drug Administration (FDA).  
        • Dr. Krammer’s lab has also assessed if antibodies in human serum play a functional role, such as neutralization of the virus and have observed that high titers of antibody in human serum correlate with high neutralizing activity in vitro against live SARS-CoV-2.  
          
        Part 2. Cell therapies 
         
        A growing number of clinical studies are underway to investigate the roles of cell therapy, particularly using mesenchymal stem cells (MSCs) and natural killer (NK) cells, to address the damage caused by COVID-19.  

        • Studies show that immunomodulatory and reparative properties of MSCs could reduce mortality rate by reversing acute inflammation of lungs, inhibiting over-activation of immune cells, protecting lung alveoli epithelial cells, promoting tissue repair, preventing pulmonary fibrosis, or improving lung function.   

        • NK cell therapy may restore the quantitative and qualitative NK cell defect associated with SARS-CoV-2 and slow the progression of severe COVID-19 disease in high-risk individuals by improving direct recognition of infected cells, suppressing viral propagation, and promoting adaptive immune responses. 
         

         

        Learning Objectives:

        • Understand the importance of serology testing in seeing the full impact of the COVID-19 disease in a population
        • Understand the role antibodies in human serum play in neutralizing against live SARS-CoV-2
        • Identify cell therapy strategies to combat tissue damage caused by COVID-19 disease
        • Summarize the main challenges facing clinical investigation into cell therapy for COVID-19 

         

         

        Webinars will be available for unlimited on-demand viewing after live event.

         

        LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.


        Show Resources
        You May Also Like
        SEP 10, 2020 9:00 AM PDT
        C.E. CREDITS
        SEP 10, 2020 9:00 AM PDT
        Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
        AUG 25, 2020 8:00 AM PDT
        C.E. CREDITS
        AUG 25, 2020 8:00 AM PDT
        DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
        OCT 08, 2020 7:00 AM PDT
        C.E. CREDITS
        OCT 08, 2020 7:00 AM PDT
        DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
        DEC 02, 2020 8:00 AM PST
        C.E. CREDITS
        DEC 02, 2020 8:00 AM PST
        DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
        JUN 23, 2020 10:00 AM PDT
        C.E. CREDITS
        JUN 23, 2020 10:00 AM PDT
        DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
        NOV 16, 2020 8:00 AM PST
        C.E. CREDITS
        NOV 16, 2020 8:00 AM PST
        Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
        Loading Comments...
        Show Resources
        Attendees
        • See more